Global Expansion HYDROS has launched internationally with US clearance in place, creating opportunities to partner with regional distributors and major health systems to deploy AI powered Aquablation in new markets. The European guideline upgrade to a strong recommendation boosts adoption potential; target high volume urology centers and offer training and service packages.

Large Patient Pool Addressable market includes tens of millions of men with LUTS BPH in the US; PROCEPT backs claims with a robust body of clinical evidence and publications; Aquablation therapy delivers durable outcomes independent of prostate size or surgeon experience, making it attractive for hospital procurement seeking standardized, reproducible results.

Growth Momentum Revenue sits in the hundred million range with strong funding; rapid growth from a smaller revenue base to a multi hundred million scale; leadership changes including CFO additions signal readiness for large scale deployments and sophisticated financial planning, which can be leveraged in multi site procurement and financing arrangements.

Regulatory Landscape HYDROS is cleared for US use with plans for international expansion; regulatory opportunities in Europe and elsewhere, with guideline support for Aquablation; sales approach should include regulatory go to market strategies and local partners to speed adoption.

Tech Differentiation AI powered Aquablation and independence from prostate size or surgeon experience differentiate HYDROS from competitors; this supports faster learning curves and standardized outcomes; position as a platform with data analytics and service contracts to win bids and enable performance based deals.